Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.575
Buy
RSI(14)
73.554
Buy
STOCH(KDJ)(9,3,3)
84.727
Overbought
ATR(14)
1.384
Low Volatility
CCI(14)
170.307
Buy
Williams %R
7.612
Overbought
TRIX(12,20)
0.501
Sell
StochRSI(14)
100.000
Buy
Bristol-Myers Squibb Co
BMY54.290USD
+1.880+3.59%
Close 12/15, 16:00（ET）Quotes delayed by 15 min
110.53BMarket Cap
18.27P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Bristol-Myers Squibb Co
Currency: USD Updated: 2025-12-15Key Insights
Bristol-Myers Squibb Co's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 11/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 52.62.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bristol-Myers Squibb Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
30
analysts
Hold
Current Rating
52.621
Target Price
+1.84%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Bristol-Myers Squibb Co Highlights
StrengthsRisks
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Overvalued
The company’s latest PE is 18.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.68B shares, decreasing 0.01% quarter-over-quarter.
Held by HACAX
Star Investor HACAX holds 605.00 shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-15The current financial score of Bristol-Myers Squibb Co is 9.31, ranking 9/159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 12.22B, representing a year-over-year increase of 2.77%, while its net profit experienced a year-over-year increase of 81.75%.
Score
Financials
6.78
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
9.75
Bristol-Myers Squibb Co's Company Valuation
Currency: USD Updated: 2025-12-15The current valuation score of Bristol-Myers Squibb Co is 8.31, ranking 22/159 in the Pharmaceuticals industry. Its current P/E ratio is 18.27, which is 37.32% below the recent high of 25.09 and 193.96% above the recent low of -17.17.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 11/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-15The current earnings forecast score of Bristol-Myers Squibb Co is 6.60, ranking 121/159 in the Pharmaceuticals industry. The average price target for Bristol-Myers Squibb Co is 53.00, with a high of 68.00 and a low of 33.10.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
30
analysts
Hold
Current Rating
52.621
Target Price
+1.84%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Bristol-Myers Squibb Co
BMY
30
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-15The current price momentum score of Bristol-Myers Squibb Co is 9.41, ranking 15/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 57.64 and the support level at 48.10, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
51.952
Buy
MA10
51.474
Buy
MA20
49.551
Buy
MA50
46.888
Buy
MA100
46.643
Buy
MA200
48.902
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-15The current institutional shareholding score of Bristol-Myers Squibb Co is 7.00, ranking 44/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 84.73%, representing a quarter-over-quarter decrease of 0.43%. The largest institutional shareholder is The Vanguard, holding a total of 194.95M shares, representing 9.58% of shares outstanding, with 2.32% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Charles Schwab Investment Management, Inc.
JP Morgan Asset Management
Geode Capital Management, L.L.C.
Norges Bank Investment Management (NBIM)
Capital International Investors
Columbia Threadneedle Investments (US)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-15The current risk assessment score of Bristol-Myers Squibb Co is 9.55, ranking 7/159 in the Pharmaceuticals industry. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.30
VaR
+2.21%
240-Day Maximum Drawdown
+32.50%
240-Day Volatility
+29.64%
Return
Best Daily Return
60 days
+7.09%
120 days
+7.09%
5 years
+11.44%
Worst Daily Return
60 days
-4.07%
120 days
-5.81%
5 years
-8.51%
Sharpe Ratio
60 days
+2.43
120 days
+1.18
5 years
+0.16
Risk Assessment
Maximum Drawdown
240 days
+32.50%
3 years
+46.79%
5 years
+51.12%
Return-to-Drawdown Ratio
240 days
-0.10
3 years
-0.17
5 years
-0.04
Skewness
240 days
-0.11
3 years
+0.57
5 years
+0.40
Volatility
Realised Volatility
240 days
+29.64%
5 years
+24.60%
Standardised True Range
240 days
+2.39%
5 years
+2.25%
Downside Risk-Adjusted Return
120 days
+194.27%
240 days
+194.27%
Maximum Daily Upside Volatility
60 days
+27.50%
Maximum Daily Downside Volatility
60 days
+20.64%
Liquidity
Average Turnover Rate
60 days
+0.62%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
-25.45%
60 days
-7.99%
120 days
-0.42%
Peer Comparison
Pharmaceuticals
Bristol-Myers Squibb Co
BMY
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Bristol-Myers Squibb Co?
The TradingKey Stock Score provides a comprehensive assessment of Bristol-Myers Squibb Co based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Bristol-Myers Squibb Co’s performance and outlook.
How do we generate the financial health score of Bristol-Myers Squibb Co?
To generate the financial health score of Bristol-Myers Squibb Co, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Bristol-Myers Squibb Co's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Bristol-Myers Squibb Co.
How do we generate the company valuation score of Bristol-Myers Squibb Co?
To generate the company valuation score of Bristol-Myers Squibb Co, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Bristol-Myers Squibb Co’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Bristol-Myers Squibb Co’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Bristol-Myers Squibb Co.
How do we generate the earnings forecast score of Bristol-Myers Squibb Co?
To calculate the earnings forecast score of Bristol-Myers Squibb Co, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Bristol-Myers Squibb Co’s future.
How do we generate the price momentum score of Bristol-Myers Squibb Co?
When generating the price momentum score for Bristol-Myers Squibb Co, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Bristol-Myers Squibb Co’s prices. A higher score indicates a more stable short-term price trend for Bristol-Myers Squibb Co.
How do we generate the institutional confidence score of Bristol-Myers Squibb Co?
To generate the institutional confidence score of Bristol-Myers Squibb Co, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Bristol-Myers Squibb Co’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Bristol-Myers Squibb Co.
How do we generate the risk management score of Bristol-Myers Squibb Co?
To assess the risk management score of Bristol-Myers Squibb Co, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Bristol-Myers Squibb Co’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Bristol-Myers Squibb Co.
